FEN164

Developed for: autism spectrum disorder
Investigated by: Fenix Innovation Group · Monash Health · Neurotech International Limited

today NCT05516407 · Ph 1/2

20222023202420252026

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1/2	NCT05516407	Apr 2021 → Sep 2022	autism spectrum disorder	Fenix Innovation Group	Unknown	Met primary

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	FEN164	ClinicalTrials.gov intervention name — accepted as the source's own label NCT05516407 ↗
Route	Oral	“Orally Administered Full-Spectrum Medicinal Cannabis Plant Extract” NCT05516407 ↗